← Back to Search

Melatonin for Vaccine Response (MAVRICS Trial)

N/A
Waitlist Available
Led By Janine Danko, MD
Research Sponsored by Walter Reed National Military Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-64
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14-21 days post vaccination
Awards & highlights

Summary

This trial will study if better sleep habits, understanding natural sleep cycles, and taking melatonin can help make the flu vaccine work better for people.

Who is the study for?
This trial is for adults aged 18-64 who can get a flu shot at a military hospital and are registered in the DEERS system. It's not for those with allergies to the flu vaccine, pregnant women, or individuals with immune-compromising conditions like HIV/AIDS, cancer, diabetes, significant heart disease or diagnosed sleep disorders.
What is being tested?
The study is looking into how sleep patterns and melatonin (a natural hormone) affect the body's response to the flu vaccine. Participants will be monitored using a Phillips Actiwatch Spectrum Plus device to track their sleep and activity rhythms.
What are the potential side effects?
Since this trial involves taking melatonin and receiving a standard flu vaccine, potential side effects may include drowsiness from melatonin and common mild reactions to vaccines such as soreness at injection site, fever or muscle aches.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 64 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14-21 days post vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14-21 days post vaccination for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Anti-influenza antibody titers
Cell-mediated immunity
Secondary study objectives
Actigraph data
Chronotype survey - Munich ChronoType Questionaire (MCTQ)
Sleep survey - Pittsburgh Sleep Quality Index (PSQI)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Melatonin GroupExperimental Treatment2 Interventions
This group will get melatonin 5mg nightly
Group II: Control GroupActive Control1 Intervention
This group will not get any treatment (melatonin)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Melatonin
2014
Completed Phase 4
~1150

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Melatonin, a hormone produced in the pineal gland, regulates circadian rhythms and has antioxidant, anti-inflammatory, and immunomodulating properties. These mechanisms can enhance the body's immune response, which is crucial for vaccine efficacy. By improving sleep quality and aligning circadian rhythms, melatonin may optimize the timing and effectiveness of immune responses, potentially leading to better vaccine outcomes.
Sustained melatonin treatment blocks body mass, pelage, reproductive, and fever responses to short day lengths in female Siberian hamsters.

Find a Location

Who is running the clinical trial?

Walter Reed National Military Medical CenterLead Sponsor
138 Previous Clinical Trials
32,788 Total Patients Enrolled
Naval Medical Research CenterFED
33 Previous Clinical Trials
2,700 Total Patients Enrolled
Janine Danko, MDPrincipal InvestigatorNaval Medical Research Center

Media Library

Melatonin Group Clinical Trial Eligibility Overview. Trial Name: NCT04953754 — N/A
Vaccine Response Research Study Groups: Melatonin Group, Control Group
Vaccine Response Clinical Trial 2023: Melatonin Group Highlights & Side Effects. Trial Name: NCT04953754 — N/A
Melatonin Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT04953754 — N/A
~71 spots leftby Sep 2025